Clinical Trial: A Study of JNJ-95597528 in Participants With Moderate to Severe Atopic Dermatitis

U.S., Nov. 18 -- ClinicalTrials.gov registry received information related to the study (NCT07230860) titled 'A Study of JNJ-95597528 in Participants With Moderate to Severe Atopic Dermatitis' on Nov. 14.

Brief Summary: The purpose of this study is to assess how well JNJ-95597528 works compared to placebo in participants with moderate to severe atopic dermatitis (AD).

Study Start Date: Feb. 13, 2026

Study Type: INTERVENTIONAL

Condition: Dermatitis, Atopic

Intervention: DRUG: JNJ-95597528

JNJ-95597528 will be administered subcutaneously.

DRUG: Placebo

Placebo will be administered subcutaneously.

Recruitment Status: NOT_YET_RECRUITING

Sponsor: Janssen Research & Development, LLC

Published by HT Digital Content Services with permis...